The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 4, 2010, Pages 223-232

  Bonkowski, Joseph ^a   Vermeulen, Lee C ^a,b   Kolesar, Jill M ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

lenalidomide; multiple myeloma; myelodysplastic syndromes

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; DEXAMETHASONE; DIGOXIN; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE;

ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BLOOD TRANSFUSION; BODY WEIGHT; CANCER RELAPSE; CHROMOSOME 5Q; CHROMOSOME DELETION; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CREATININE CLEARANCE; CROHN DISEASE; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DYSGEUSIA; EYE DISEASE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; INSOMNIA; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRENATAL EXPOSURE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SOMNOLENCE; STEM CELL TRANSPLANTATION; STOMATITIS; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; TUMOR GROWTH; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VOMITING;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DRUG COSTS; DRUG INTERACTIONS; HUMANS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 78650465562     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209351967     Document Type: Article

References (19)

1. Coutre S. Myelodysplastic syndromes: disease overview and therapy options. Manag Care 2008 ; 17 (7). 3-8.
2. Giagounidis A., Fenaux P., Mufti GJ, Muus P., Platzbecker U., Sanz G. et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008 ; 87 (5). 345-52.
3. The NCCN Clinical Practice Guidelines in OncologyTM MYELODYSPLASTIC SYNDROMES (Version 1.2009) © 2009 National Comprehensive Cancer Network, Inc Available at: NCCN.org (accessed date June 8, 2009). To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
4. Tuscano JM Multiple myeloma: epidemiology and therapeutic options. Manag Care 2008 ; 17 (7). 9-15.
5. The NCCN Clinical Practice Guidelines in OncologyTM MULTIPLE MYELOMA (Version 1.2010). © 2009 National Comprehensive Cancer Network, Inc Available at: NCCN.org (accessed date June 8, 2009). To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
6. Revlimid (lenalidomide). [Package insert] Summit, NJ ; Celgene Corporation, 2009.
7. Raab MS, Podar K., Breitkreutz I., Richardson PG, Anderson KC Multiple myeloma. Lancet 2009 ; 374 (9686). 324-39.
8. Jadersten M., Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009 ; 265 (3). 307-28.
9. Chen N., Lau H., Kong L., Kumar G., Zeldis JB, Knight R. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007 ; 47: 1466-75.
10. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 ; 355 (14). 1456-65.
11. Raza A., Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase II study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008 ; 111 (1). 86-93.
12. Weber DM, Chen C., Niesvizky R., Prince HM, Harousseau JL, Dmoszynska A. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 ; 357 (21). 2133-42.
13. Dimopoulos M., Spencer A., Attal M., Wang M., Belch A., Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 ; 357 (21). 2123-32.
14. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A., Geyer SM, Kabat B. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005 ; 106: 4050-3.
15. Patel PH, Kondagunta GV, Schwartz L., Ishill N., Bacik J., DeLuca J. et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 2008 ; 26: 273-6.
16. Wiernik PH, Lossos IS, Tuscano JM, Justice G., Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008 ; 26 (30). 4952-7.
17. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L. et al. Lenalidomide and rituximab in Waldenstrom macroglobulinemia. Clin Cancer Res 2009 ; 15: 355-60.
18. Mansfield JC, Parkes M., Hawthorne AB, Forbes A., Probert CS, Perowne RC et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 2007 ; 26 (3). 421-30.
19. Klasco RK ed. DRUGDEX< System [electronic version]. Greenwood Village, CO: Thomson Micromedex, Available at: http://www.thomsonhc.com (accessed date June 30, 2009 ).